Literature DB >> 6148444

Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines.

G Morstyn, A Russo, D N Carney, E Karawya, S H Wilson, J B Mitchell.   

Abstract

Human lung cancers of distinct histology exhibit different responses to radiation therapy in vivo. For examination of the basis of this phenomenon, the radiation survival curves and levels of relevant enzymes were determined in 16 lung cancer cell lines derived from tumors of different histology. These included lines from 5 adenocarcinomas, 7 small cell tumors, 3 variant small cell tumors, and 1 large cell tumor. These findings were compared to those obtained with the use of a normal skin fibroblast cell line. Whether cloned in liquid culture or soft agarose, cell lines had similar radiation survival curves. These curves were consistent with the apparent in vivo radiation responsiveness of the tumors. Although considerable heterogeneity in radiation survival curves was observed among the cell lines, cells from large cell lines and small variant lines had pronounced shoulders and extrapolation numbers (n) from 5.6 to 14. In contrast, cells from small cell lines and adenocarcinoma cell lines were more "sensitive" (-n values of 1-3.3). In these cell lines, levels of DNA polymerase beta, glutathione (GSH), GSH transferase, GSH reductase (NAD(P)H), gamma-glutamyltransferase did not correlate with radiation parameters of sensitivity. DNA polymerase beta and GSH levels were, however, higher than those in a line of normal skin fibroblasts. These cell lines may be useful in identifying the basis of the variable responsiveness of human lung cancer cells to ionizing radiation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148444

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

Review 1.  The impact of surgery on the multidisciplinary treatment of bronchogenic small cell carcinoma (updated review including ongoing studies).

Authors:  W Theuer; O Selawry; K Karrer
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  Effect of selenium compounds and thiols on human mammary tumor cells.

Authors:  L Yan; J A Yee; L M Boylan; J E Spallholz
Journal:  Biol Trace Elem Res       Date:  1991-08       Impact factor: 3.738

3.  Cooperation of c-raf-1 and c-myc protooncogenes in the neoplastic transformation of simian virus 40 large tumor antigen-immortalized human bronchial epithelial cells.

Authors:  A M Pfeifer; G E Mark; L Malan-Shibley; S Graziano; P Amstad; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

Review 4.  Review: biologic heterogeneity of cancer metastases.

Authors:  I J Fidler
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

Review 5.  Engineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic Delivery.

Authors:  Jeannine M Coburn; David L Kaplan
Journal:  Bioconjug Chem       Date:  2015-03-02       Impact factor: 4.774

6.  v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer.

Authors:  M Mabry; T Nakagawa; B D Nelkin; E McDowell; M Gesell; J C Eggleston; R A Casero; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

7.  Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo.

Authors:  Yuki Shibata; Hironobu Yasui; Kei Higashikawa; Naoki Miyamoto; Yuji Kuge
Journal:  PLoS One       Date:  2019-12-04       Impact factor: 3.240

8.  Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer cell lines?

Authors:  B G Campling; K Baer; H M Baker; Y M Lam; S P Cole
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

9.  In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.

Authors:  D W Siemann; K L Beyers
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.